Molecular classification of 46 newly diagnosed DLBCLs
DLBCL . | GCBL/Type 3/ABL . | % malignant cells . | t(14;18): karyotype . | t(14;18): PCR . | REL copy no. . | % REL-positive nuclei . |
---|---|---|---|---|---|---|
1 | ABL | 90 | - | - | 2 | 12 |
2 | GCBL | 85 | - | - | 3 | 15 |
3 | Type 3 | 90 | - | - | 2 | NE |
4 | Type 3 | 70 | NE | NE | 2 | 2 |
5 | ABL | 90 | N | - | 1 | 90 |
6 | ABL | 50 | - | - | 2 | 80 |
7 | ABL | 90 | NE | NE | 3 | NE |
8 | GCBL | 90 | F | + | 2 | 85 |
9 | GCBL | 80 | + | + | 2 | 50 |
10 | ABL | 50 | - | NE | 4 | 95 |
11 | ABL | 90 | + | - | 2 | 90 |
12 | GCBL | 50 | F | - | 5 | 20 |
13 | Type 3 | 90 | F | - | 2 | 40 |
14 | GCBL | 95 | - | NE | 2 | 40 |
15 | GCBL | 95 | + | + | 2 | 5 |
16 | GCBL | 90 | + | + | 1 | 5 |
17 | Type 3 | 85 | - | - | 5 | 85 |
18 | GCBL | 60 | - | NE | 2 | 90 |
19 | GCBL | 75 | + | + | 1 | NE |
20 | GCBL | 90 | - | NE | 5 | 10 |
21 | Type 3 | 95 | F | NE | 1 | 20 |
22 | ABL | 40 | - | - | 1 | 70 |
23 | ABL | 30 | N | - | 2 | 25 |
24 | Type 3 | 85 | - | - | 1 | NE |
25 | Type 3 | 90 | - | - | 3 | 2 |
26 | GCBL | 95 | F | - | 2 | 80 |
27 | GCBL | 85 | - | - | 4 | 90 |
28 | GCBL | 90 | - | - | 3 | 95 |
29 | ABL | 30 | F | NE | NE | 90 |
30 | Type 3 | 60 | F | - | 5 | NE |
31 | Type 3 | 65 | F | - | 1 | 5 |
32 | ABL | 85 | + | + | 2 | NE |
33 | GCBL | 30 | + | NE | 1 | 5 |
34 | ABL | 95 | - | NE | 4 | NE |
35 | ABL | 40 | - | - | 2 | 10 |
36 | Type 3 | 95 | - | - | 2 | 90 |
37 | Type 3 | 90 | F | - | 2 | 95 |
38 | ABL | 95 | - | - | 2 | 50 |
39 | GCBL | 95 | NE | NE | NE | 15 |
40 | ABL | 90 | NE | NE | NE | 90 |
41 | Type 3 | 90 | F | - | 1 | 85 |
42 | GCBL | 90 | - | + | 4 | 15 |
43 | GCBL | 95 | N | NE | 2 | 5 |
44 | Type 3 | 50 | F | - | 2 | 20 |
45 | GCBL | 95 | - | - | 1 | 85 |
46 | GCBL | 80 | - | - | 141 | 1 |
DLBCL . | GCBL/Type 3/ABL . | % malignant cells . | t(14;18): karyotype . | t(14;18): PCR . | REL copy no. . | % REL-positive nuclei . |
---|---|---|---|---|---|---|
1 | ABL | 90 | - | - | 2 | 12 |
2 | GCBL | 85 | - | - | 3 | 15 |
3 | Type 3 | 90 | - | - | 2 | NE |
4 | Type 3 | 70 | NE | NE | 2 | 2 |
5 | ABL | 90 | N | - | 1 | 90 |
6 | ABL | 50 | - | - | 2 | 80 |
7 | ABL | 90 | NE | NE | 3 | NE |
8 | GCBL | 90 | F | + | 2 | 85 |
9 | GCBL | 80 | + | + | 2 | 50 |
10 | ABL | 50 | - | NE | 4 | 95 |
11 | ABL | 90 | + | - | 2 | 90 |
12 | GCBL | 50 | F | - | 5 | 20 |
13 | Type 3 | 90 | F | - | 2 | 40 |
14 | GCBL | 95 | - | NE | 2 | 40 |
15 | GCBL | 95 | + | + | 2 | 5 |
16 | GCBL | 90 | + | + | 1 | 5 |
17 | Type 3 | 85 | - | - | 5 | 85 |
18 | GCBL | 60 | - | NE | 2 | 90 |
19 | GCBL | 75 | + | + | 1 | NE |
20 | GCBL | 90 | - | NE | 5 | 10 |
21 | Type 3 | 95 | F | NE | 1 | 20 |
22 | ABL | 40 | - | - | 1 | 70 |
23 | ABL | 30 | N | - | 2 | 25 |
24 | Type 3 | 85 | - | - | 1 | NE |
25 | Type 3 | 90 | - | - | 3 | 2 |
26 | GCBL | 95 | F | - | 2 | 80 |
27 | GCBL | 85 | - | - | 4 | 90 |
28 | GCBL | 90 | - | - | 3 | 95 |
29 | ABL | 30 | F | NE | NE | 90 |
30 | Type 3 | 60 | F | - | 5 | NE |
31 | Type 3 | 65 | F | - | 1 | 5 |
32 | ABL | 85 | + | + | 2 | NE |
33 | GCBL | 30 | + | NE | 1 | 5 |
34 | ABL | 95 | - | NE | 4 | NE |
35 | ABL | 40 | - | - | 2 | 10 |
36 | Type 3 | 95 | - | - | 2 | 90 |
37 | Type 3 | 90 | F | - | 2 | 95 |
38 | ABL | 95 | - | - | 2 | 50 |
39 | GCBL | 95 | NE | NE | NE | 15 |
40 | ABL | 90 | NE | NE | NE | 90 |
41 | Type 3 | 90 | F | - | 1 | 85 |
42 | GCBL | 90 | - | + | 4 | 15 |
43 | GCBL | 95 | N | NE | 2 | 5 |
44 | Type 3 | 50 | F | - | 2 | 20 |
45 | GCBL | 95 | - | - | 1 | 85 |
46 | GCBL | 80 | - | - | 141 | 1 |
NE indicates not evaluable; N, normal; F, failure.